Global Nuclear Medicine Radioisotopes Market Size By Type (Thallium-201 (Tl-201), Iodine (I-123)), By Application (Tumor, Heart Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global Nuclear Medicine Radioisotopes Market was valued at USD 6.1 billion in 2023 and is projected to surpass USD 12.4 billion by 2031, growing at a CAGR of 9.3% during the forecast period from 2023 to 2031. The market's expansion is primarily driven by the increasing prevalence of chronic diseases, especially cancer and cardiovascular disorders, and the growing application of radioisotopes in diagnostic imaging and targeted therapies. Technological advancements in nuclear medicine imaging modalities and increased government investments in healthcare infrastructure are further supporting market growth.

Drivers:

1. Rising Incidence of Cancer and Cardiac Diseases:

The increasing burden of chronic diseases, particularly cancer and heart-related disorders, has escalated the demand for precise and early diagnostic methods. Radioisotopes such as Technetium-99m and Iodine-131 are widely used in PET and SPECT imaging, contributing significantly to disease detection and management.

2. Technological Advancements in Radiopharmaceuticals:

Continued innovation in molecular imaging, including hybrid imaging systems (PET/CT and SPECT/CT), is enhancing diagnostic accuracy and expanding the clinical applications of radioisotopes.

3. Expansion of Diagnostic Imaging Facilities:

The global expansion of advanced diagnostic centers, particularly in developing economies, is facilitating the increased adoption of nuclear medicine procedures, thus driving the market.

Restraints:

1. Short Half-Life of Radioisotopes:

Many radioisotopes have a short half-life, which limits their shelf life and complicates logistics and storage. This requires a reliable and timely supply chain that can be challenging to maintain.

2. Stringent Regulatory Framework:

The use of radioactive materials is heavily regulated due to safety concerns. Complex approval processes and compliance requirements can slow down product development and market access.

Opportunity:

1. Growing Demand in Emerging Markets:

Rapid healthcare infrastructure development and increasing awareness in countries across Asia-Pacific and Latin America offer substantial growth potential for nuclear medicine radioisotopes.

2. Development of Targeted Alpha Therapy (TAT):

TAT is emerging as a highly promising treatment modality in oncology. The development of novel isotopes like Actinium-225 is opening new avenues for precision medicine and targeted cancer therapies.

Market by System Type Insights:

In 2023, the Diagnostic Radioisotopes segment dominated the market, with Technetium-99m being the most commonly used isotope in medical diagnostics. This dominance is attributed to its extensive usage in imaging for bone scans, cardiac perfusion, and tumor detection. The Therapeutic Radioisotopes segment, led by Iodine-131 and Lutetium-177, is projected to grow significantly owing to the rising popularity of targeted radionuclide therapy in oncology and endocrinology.

Market by End-use Insights:

Hospitals emerged as the largest end-use segment in 2023, accounting for over 45% of the total market share. This is due to the high volume of diagnostic and therapeutic procedures conducted in hospital settings. Diagnostic centers are expected to witness rapid growth during the forecast period due to increasing patient preference for outpatient imaging services and cost-effective scanning solutions.

Market by Regional Insights:

North America held the largest market share in 2023, driven by the presence of leading radioisotope producers, advanced healthcare infrastructure, and high prevalence of cancer. Meanwhile, the Asia-Pacific region is forecasted to record the highest CAGR, propelled by rising healthcare investments, growing awareness, and increased adoption of nuclear medicine technologies in countries like China, India, and South Korea.

Competitive Scenario:

Prominent players in the Global Nuclear Medicine Radioisotopes Market include Curium Pharma, GE Healthcare, Cardinal Health, Lantheus Holdings, Inc., Siemens Healthineers, Nordion Inc., IRE Elit, and Jubilant Radiopharma. These companies are actively investing in product development, supply chain optimization, and strategic collaborations to gain competitive advantages.

Key Developments:

In 2023, GE Healthcare announced the expansion of its radiopharmaceutical production capabilities across Europe and North America.

In 2024, Curium Pharma partnered with academic institutions to develop next-generation therapeutic radioisotopes for cancer treatment.

Siemens Healthineers launched a new SPECT/CT system in 2025, integrating AI-powered diagnostic enhancements to support precision imaging.

Scope of Work – Global Nuclear Medicine Radioisotopes Market

Report Metric Details

Market Size (2023) USD 6.1 billion

Projected Market Size (2031) USD 12.4 billion

CAGR (2023–2031) 9.3%

Market Segments System Type (Diagnostic, Therapeutic), End-use, Region

Growth Drivers Rising incidence of cancer and cardiac diseases, technological advancements in radiopharmaceuticals

Opportunities Expansion in emerging markets, advancements in targeted alpha therapy

FAQs:

1) What is the current market size of the Global Nuclear Medicine Radioisotopes Market?

The market was valued at USD 6.1 billion in 2023.

2) What is the major growth driver of the Global Nuclear Medicine Radioisotopes Market?

The primary growth driver is the rising incidence of chronic diseases, especially cancer and cardiovascular conditions.

3) Which is the largest region during the forecast period in the Global Nuclear Medicine Radioisotopes Market?

North America is the largest region, owing to its robust healthcare system and established radioisotope infrastructure.

4) Which segment accounted for the largest market share in the Global Nuclear Medicine Radioisotopes Market?

The Diagnostic Radioisotopes segment held the largest share in 2023.

5) Who are the key market players in the Global Nuclear Medicine Radioisotopes Market?

Key players include GE Healthcare, Curium Pharma, Siemens Healthineers, Cardinal Health, and Lantheus Holdings, Inc.